#oral medication

Structure Therapeutics reporta resultados alentadores de Fase 2 para su agonista del receptor GLP-1 oral, avanzando una alternativa en forma de píldora a los medicamentos inyectables para pérdida de peso y diabetes.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.